- Home
- Your Messages
-
Smartest Doc
Test your clinical knowledge against other physicians in the USA by taking our FREE daily quiz!
We invite you to take the "ASCO Review: Focus on breast cancer Quiz"
Current Top Players:
1) Dr. Hassan Ghazal
2) Dr. Amer Khouri
3) Dr. Andrew Schneider
>> Live LeaderboardNew! PHYSICIAN REVIEW
Assess your general knowledge at the topic level with your personalized scorecard.
Thousands of multiple-choice questions pinpoint your areas of expertise and prep you for exams.
- Physician Jobs (533)
- More
- Other Specialty
Oncology News & Articles
Looking for the latest in oncology clinical literature? You've found the right page. MDLinx Oncology medical editors comb through the top peer-reviewed clinical journals for the articles they think will make a difference to you and your practice. You'll find them organized here by topic including breast, hematologic, thoracic, gastrointestinal and genitourinary cancers. In a matter of minutes, oncologists, oncology nurses, physician assistants and the whole cancer care team can stay current on the literature as it is published.
On this page, you'll also find MDLinx exclusive content, including monthly highlights from our physician editor, D. Scott Cunningham, MD, PhD. We feature clinical pearls as well, from The Smartest Oncologist to oncology topics in The Smartest Pediatrician daily quiz challenges.
Your Unread Messages in Oncology
See All >> Messages include industry-sponsored communications and special communications from MDLinx-
Patients 50+ may be at increased risk for pneumococcal disease. Learn what you can do. -
Smartest Doc Challenge
MDLinx
Pediatric Oncology Clinical Pearls -
D Scott Cunningham MD, PhD
Site Editor, MDLinx
Transition rates for adenomas to CRC -
Jill Baker
MDLinx Career Center
New Jobs in Your Specialty -
MDLinx Top Read
MDLinx
Are your journals collecting cobwebs? -
MDLinx Conference Center
MDLinx
June Conference Calendar
Clinical Pearls in Oncology
- The ZORO study demonstrated that the addition of goserelin to neoadjuvant chemotherapy for early breast cancer in premenopausal women resulted in no change in post-chemotherapy rates of amenorrhea
- A little over 50% of tumors in women with ER-positive, node-negative breast cancers will have a RS <18, and current data suggests that these women are UNLIKELY to receive a benefit from adjuvant chemotherapy
- In patients with completely resected ER-positive DCIS when the surgical specimen also has LCIS, consider breast MRI screening in addition to mammography due to the lower sensitivity of mammograms for lobular disease
Highlights in Oncology
VEGFR-1 is a prognostic marker for HCC
As reported in the Journal of Pathology, the expression of vascular endothelial growth factor receptor (VEGFR)-1 is elevated in invasive hepatocellular cancer (HCC) specimens. In a study based on 135 HCC specimens, elevated VEGFR-1 was also associated with worse recurrence-free and overall survival.
Read the article summaryHCC risk increased in patients with AIDS
As reported in Cancer, researchers from the NCI have reported that patients with AIDS have a 4-fold increased risk of HCC compared to the general population. The study findings were based on 615,150 patients with AIDS between 1980 and 2009. The risk for HCC in patients with AIDS was essentially the same during the monotherapy/dual therapy and highly active anti-retroviral therapy eras.
Read the article summaryRAB25 is a prognostic marker for ovarian cancer
As reported in the International Journal of Cancer Research and Treatment, the pre-operative level of RAB25 is a predictor of disease-free survival (HR=18.2) and overall survival (HR=33.6) in patients with ovarian cancer. The study involved 36 and 16 women with ovarian cancer and benign tumors, respectively. The pre-operative cell-free DNA of genes (B2M, RAB25, CLDN4, and ABCF2) were measured and RAB25 was shown to be an independent prognostic factor.
Read the article summaryMost Popular Oncology Articles
Last month's top read Top Articles of 20121 Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202) Journal of Clinical Oncology, April 15, 2013
2 Neoadjuvant chemotherapy with or without zoledronic acid in early breast cancer: a randomized biomarker pilot study Clinical Cancer Research, May 6, 2013
3 Mortality after radical prostatectomy or external beam radiotherapy for localized prostate cancer Journal of the National Cancer Institute, May 1, 2013
4 Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma Annals of Oncology, May 6, 2013
5 Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles The Lancet, April 23, 2013
6 Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial The Lancet Oncology, May 17, 2013
7 Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial The Lancet Oncology, May 3, 2013
8 Association of metformin use with cancer incidence and mortality: A meta-analysis Cancer Epidemiology, April 22, 2013 Review Article
9 Radiotherapy or tamoxifen after conserving surgery for breast cancers of excellent prognosis: British Association of Surgical Oncology (BASO) II trial European Journal of Cancer, April 2, 2013
10 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, May 3, 2013
11 Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors Cancer, April 12, 2013
12 Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: Results from the HERA Trial Journal of Clinical Oncology, April 25, 2013
13 Thalidomide versus active supportive care for maintenance in patients with malignant mesothelioma after first-line chemotherapy (NVALT 5): an open-label, multicentre, randomised phase 3 study The Lancet Oncology, May 3, 2013
14 AVEREL: A randomized phase III trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer Journal of Clinical Oncology, April 15, 2013
15 Survival of pediatric patients after relapsed osteosarcoma: The St. Jude Childrens Research Hospital experience Cancer, May 2, 2013
16 Specific adverse events predict survival benefit in patients treated with tamoxifen or aromatase inhibitors: An International Tamoxifen Exemestane Adjuvant Multinational Trial analysis Journal of Clinical Oncology, April 30, 2013
17 Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer British Journal of Cancer, May 7, 2013
18 Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis Journal of the National Cancer Institute, April 19, 2013 Evidence Based Medicine
19 Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study Journal of Clinical Oncology, April 29, 2013
20 Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial The Lancet Oncology, April 23, 2013
Indexed Journals in Oncology: Journal of Clinical Oncology, Cancer Research, Annals Oncology more
Other Topics in Oncology
Register now to view all the MDLinx contents (FREE)!
- Stay current on the latest literature, research and clinical news
- Get special communications and offers from MDLinx and our sponsors
- Receive invitations to paid market research
Login
Stay current - Media Tool
♦ Subscribe to our free RSS feeds:
Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More ♦
♦ Follow Us on Twitter
Twitter is a rich source of instantly updated information. Join today and follow @MDLinx to start receiving tweets. Learn More ♦
Close